Syouji Sasaya

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
An 83-year-old male with Stage IV gastric cancer of performance status 1 (PS 1) was treated with fluoropyrimidine (TS-1) since January 2003 in our department. As the patient exhibited decreased renal function due to his age, we set the basic dose at 80% of the recommended dose of 80 mg/body/week. We administered 11 four-week cycles, each with a two-week(More)
  • 1